艾立康药业股份有限公司

艾立康药业股份有限公司

浙江省嘉兴市浙江省海宁市水月亭东路500号鹃湖科技创新园4幢

2021

200至249

不愿意公开

许可项目：药品生产；保健食品生产；第二类医疗器械生产；第三类医疗器械生产；药品进出口；货物进出口；技术进出口(依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目以审批结果为准)。一般项目：化工产品生产（不含许可类化工产品）；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广(除依法须经批准的项目外，凭营业执照依法自主开展经营活动)。

经验丰富的研发人员,生产能力,产品线丰富,合同定制（CRO,CMO）,接受小额订单,优质服务

314400

www.alicornpharma.com

制造商

中/南美洲,中东,非洲,亚洲

Tofacitinib Citrate(540737-29-9);Tofacitinib Citrate intermediate(477600-73-0);Tofacitinib Citrate intermediate(477600-74-1);Avatrombopag Maleate(677007-74-8);Avatrombopag Maleate intermediate(570403-14-4);Dronedarone Hydrochloride(141625-93-6);Dronedarone Hydrochloride intermediate(141645-23-0);Azilsartan Medoxomil Potassium(863031-24-7);Azilsartan Medoxomil Potassium intermediate(147403-03-0);Azilsartan Medoxomil Potassium intermediate(863031-21-4);Betahistine Mesylate(54856-23-4）;Pimavanserin Tartrate(706782-28-7);Pimavanserin Tartrate intermediate(1837794-51-0);Iguratimod(123663-49-0);BempedoicAcid(738606-46-7);BempedoicAcid intermediate(2570179-39-2);BempedoicAcid intermediate(413624-71-2);BempedoicAcid intermediate(123469-92-1);Finerenone(1050477-31-0);Finerenone intermediate(1050477-43-4);Finerenone intermediate(1050477-44-5);Finerenone intermediate(1050477-45-6);Finerenone intermediate(1050477-27-4）;Ritlecitinib(2192215-81-7);Ritlecitinib Base(1792180-81-4);Ritlecitinib intermediate(1227917-63-6);Ritlecitinib intermediate(2295746-50-6);Ritlecitinib intermediate(2922238-87-5);Ritlecitinib intermediate(1207947-49-6);Ritlecitinib intermediate(1207853-23-3);Ritlecitinib intermediate(2042650-70-2);Etrasimod Arginine(1206123-97-8);Etrasimod Arginine intermediate(1206124-13-1);Etrasimod Arginine intermediate(957208-65-0);Etrasimod Arginine intermediate(1206124-34-6);Etrasimod Arginine intermediate(1206123-37-6);Mavacamten(1642288-47-8);Mavacamten intermediate(69998-14-7);Mavacamten intermediate(887581-47-7);Bicyclol(118159-48-1);Bicyclol intermediate(105868-34-6);Bicyclol intermediate(211996-66-6);Imrecoxib(395683-14-4）;Imrecoxib intermediate(10297-73-1);Imrecoxib intermediate(50413-24-6);Imrecoxib intermediate(93114-06-8);Imrecoxib intermediate(479679-98-6);Imrecoxib intermediate(395683-22-4);Baloxavir(1985606-14-1);Baloxavir intermediate(2136287-66-4);Baloxavir intermediate(1985607-83-7);Baloxavir intermediate(1985607-70-2);Lobeglitazone Sulfate(763108-62-9);Lobeglitazone Sulfate intermediate(607723-33-1);Lobeglitazone Sulfate intermediate(607722-95-2);Lobeglitazone Sulfate intermediate(607723-87-5);Lobeglitazone Sulfate intermediate(607723-69-3);Tofacitinib Tablets;Moxifloxacin Eye Drops;Indobufen Tablets;Methocarbamol Tablets;Diquafosol Tetrasodium Eye Drops;Pranoprofen Eye Drops;Alendronate Sodium Tablets;Agomelatine Tablets;Fluvoxamine Maleate Tablets;Brivaracetam Extended-Release Tablets;Brivaracetam Oral Solution;Rupatadine Fumarate Oral Solution;Dapsone Gels;Pimavanserin Capsules;Butylphthalide Injections & Soft Capsules;Tofacitinib Extended-Release Tablets;Dronedarone Hydrochloride Tablets;Betahistine Mesylate Tablets;Iguratimod Tablets;Azilsartan Medoxomil Potassium Tablets;Faropenem Sodium Cranules(For Children）;Iron Protein Succinylate Oral Solution;Empagliflozin & Metformin Extended-Release Tablets;Linagliptin & Metformin Extended-Release Tablets;Citrus Flavonoids Tablets;Pemafibrate Tables;Pyrazinamide Tablets;Mirogabalin Besylate Tables;Allisartan Isoproxil Tables;Imrecoxib Tables;Finerenone Tablets;Magnesium Isoglycyrrhizinate Injections;Bicyclol Tabels;Bempedoic Acid Tables;Nebivolol Tables;Cenobamate Tablets;Ritlecitinib Capsules;Upadacitinib Extended-Release Tablets;Baloxavir Tables

第二十三届世界制药原料中国展

2025-03-06至2025-07-31

W7A02

Active Pharmaceutical Ingredients;Intermediates & Fine Chemicals;Finished Dosage;CMO & CRO